National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report.

[1]  Anita Lawitschka,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  Daniel Wolff,et al.  Measuring Therapeutic Response in Chronic Graft-versus-host-disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus- Host Disease: Iv. Response Criteria Working Group Report , 2022 .

[3]  D. Miklos,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  K. Washington,et al.  NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  H. Greinix,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .

[6]  Paul J Martin,et al.  How we treat chronic graft-versus-host disease. , 2015, Blood.

[7]  T. Panzarella,et al.  Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial , 2014 .

[8]  Ö. Bostan,et al.  The Role of Cardiovascular T2*MRI and Tissue Doppler Measurement in Assesment of Cardiac Status in β-Thalassemia Major , 2014 .

[9]  S. Steinberg,et al.  NIH response criteria measures are associated with important parameters of disease severity in patients with chronic GVHD , 2014, Bone Marrow Transplantation.

[10]  B. Storer,et al.  Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease , 2014, Haematologica.

[11]  P. Tugwell,et al.  Toward a Generalized Framework of Core Measurement Areas in Clinical Trials: A Position Paper for OMERACT 11 , 2014, The Journal of Rheumatology.

[12]  P. Tugwell,et al.  Updating the OMERACT Filter at OMERACT 11 , 2014, The Journal of Rheumatology.

[13]  J. Goldberg,et al.  Assessment of Joint and Fascia Manifestations in Chronic Graft‐Versus‐Host Disease , 2014, Arthritis & rheumatology.

[14]  W. Wood,et al.  Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  Khaled Bouri,et al.  Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012. , 2014, JAMA.

[16]  Harlan M. Krumholz,et al.  Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. , 2014, JAMA.

[17]  S. Goodman,et al.  Opening the FDA black box. , 2014, JAMA.

[18]  S. Svegliati,et al.  Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. , 2013, Blood.

[19]  B. Kurland,et al.  Measurement of oral chronic GVHD: results from the Chronic GVHD Consortium , 2013, Bone Marrow Transplantation.

[20]  B. Sandmaier,et al.  Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. , 2013, Blood.

[21]  B. Storer,et al.  Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  B. Storer,et al.  Clinical benefit of response in chronic graft-versus-host disease. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  B. Kurland,et al.  Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. , 2012, Blood.

[24]  T. Braun,et al.  Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  B. Kurland,et al.  Validation of measurement scales in ocular graft-versus-host disease. , 2012, Ophthalmology.

[26]  J. Bijlsma,et al.  The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment. , 2012, Autoimmunity reviews.

[27]  D. Parenti,et al.  Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis--results of a crossover randomized study. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[28]  M. Petri,et al.  A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. , 2011, Arthritis and rheumatism.

[29]  Li Li,et al.  A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  B. Storer,et al.  Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. , 2011, Blood.

[31]  B. Kurland,et al.  Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium , 2011, Haematologica.

[32]  J. Perkins,et al.  Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids , 2011, Haematologica.

[33]  Stephanie J. Lee,et al.  Treatment of chronic graft-versus-host disease: Past, present and future , 2011, The Korean journal of hematology.

[34]  B. Kurland,et al.  Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. , 2011, Blood.

[35]  R. Storb,et al.  Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. , 2011, Blood.

[36]  David T Felson,et al.  UvA-DARE (Digital Academic Repository) American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials , 2011 .

[37]  E. Holler,et al.  Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[38]  C. Cleeland,et al.  A New Measure Of Symptom Burden In Chronic Graft-Versus-Host Disease , 2010 .

[39]  A. Rademaker,et al.  Skin response using NIH consensus criteria vs Hopkins scale in a phase II study for steroid-refractory chronic GVHD , 2009, Bone Marrow Transplantation.

[40]  B. Storer,et al.  Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. , 2009, Blood.

[41]  B. Storer,et al.  Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[42]  L. Bouzas,et al.  A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. , 2008, Blood.

[43]  Philippe Marteau,et al.  A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. , 2007, Gastroenterology.

[44]  R. Soiffer,et al.  Quality of life associated with acute and chronic graft-versus-host disease , 2006, Bone Marrow Transplantation.

[45]  S. Hirschfeld,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[46]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[47]  E. Cook,et al.  Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[48]  H. Deeg,et al.  Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. , 2002, Blood.

[49]  D. Gladman,et al.  Systemic lupus erythematosus disease activity index 2000. , 2002, The Journal of rheumatology.

[50]  P. Rutgeerts,et al.  A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. , 2002, Gastroenterology.

[51]  J J Anderson,et al.  Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. , 2001, Arthritis and rheumatism.

[52]  S. Davies,et al.  Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[53]  B. Craven,et al.  Quality of life and psychological distress of bone marrow transplant recipients: the ‘time trajectory’ to recovery over the first year , 1998, Bone Marrow Transplantation.

[54]  A. Bonomi,et al.  Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale , 1997, Bone Marrow Transplantation.

[55]  J J Anderson,et al.  American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[56]  D A Isenberg,et al.  The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. , 1993, The Quarterly journal of medicine.

[57]  E. Schned,et al.  Derivation of the SLEDAI. , 1993, Arthritis and rheumatism.

[58]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[59]  M. Liang,et al.  Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. , 1989, Arthritis and rheumatism.

[60]  Jean E. Sanders,et al.  Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. , 1988, Blood.

[61]  K. Sullivan,et al.  Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. , 1981, Blood.

[62]  A. Claudy,et al.  Disease activity in systemic lupus erythematosus , 1979, Clinical and experimental dermatology.

[63]  F Kern,et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.

[64]  B. Sandmaier,et al.  Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. , 2014, Blood.

[65]  S. Steinberg,et al.  Validation of the National Institutes of Health chronic GVHD Oral Mucosal Score using component-specific measures , 2014, Bone Marrow Transplantation.

[66]  M. Pasquini,et al.  2013 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. , 2013, Clinical transplants.

[67]  S. Grupp,et al.  Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group study. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[68]  M. Mohty,et al.  Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[69]  B. Storer,et al.  Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[70]  R. Arceci.  Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease , 2009 .

[71]  P. Lachenbruch,et al.  Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[72]  J. Ware.  SF-36 health survey: Manual and interpretation guide , 2003 .

[73]  H. Deeg,et al.  Thalidomide for treatment of patients with chronic graft-versus-host disease. , 2000, Blood.

[74]  John E. Ware,et al.  SF-36 physical and mental health summary scales : a user's manual , 1994 .